August 01, 2025

Cannabis Use Disorder Linked to Oral Cancer

Cannabis use disorder significantly increased the 5-year risk of oral cancer among screened adults in a multicenter cohort study.

Conexiant

July 23, 2025

Mouth Taping Shows Limited Benefit, Possible Risk

A review of 10 studies with 233 patients found limited benefits and potential safety risks associated with mouth taping for obstructive sleep apnea and mouth breathing during sleep.

Conexiant

July 22, 2025

Might That Lip Lesion Be BCC?

New research has documented 4 cases of lip basal cell carcinoma presenting as smooth yellow nodules—a rare clinical presentation that may be mistaken for benign mesenchymal tumors, potentially resulting in diagnostic delays and postponed treatment.

Conexiant

July 18, 2025

New Guideline Sets Standards for Sinus Surgery

A new guideline outlines when surgery is appropriate for chronic rhinosinusitis, urging clinicians to confirm diagnosis, assess candidacy, and consider long-term management needs.

Conexiant

July 03, 2025

Is HPV-Driven SNSCC Its Own Disease?

Researchers identified key genetic differences between HPV-associated and HPV-independent sinonasal squamous cell carcinoma, revealing distinct mutations, survival risks, and potential treatment targets.

Conexiant

June 20, 2025

Hormone Levels May Guard Against MetS

A large national study of U.S. women ages 12 to 49 found that higher levels of testosterone and sex hormone–binding globulin were linked to lower odds of metabolic syndrome, with differences observed across racial and ethnic groups.

Conexiant

June 19, 2025

Chronic Cannabis Use Linked to Vascular Impairment

A new cross-sectional study in healthy adults found that chronic marijuana smoking and edible THC use were linked to reduced endothelial function, an early marker of vascular disease risk.

Conexiant

June 17, 2025

FDA-Approved Sweetener Found in Vapes

New laboratory analysis found widespread use of neotame, a potent artificial sweetener, in most disposable e-cigarettes sold in the United States, including nicotine-free and nicotine-analogue products.

Conexiant

June 16, 2025

Cytisinicline Shows Efficacy In Smoking Cessation Trial 

A phase 3 randomized clinical trial found that cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, improved smoking cessation rates compared with placebo, with higher abstinence rates and reduced craving over 24 weeks.

Conexiant